OpenAI is in discussions with the US Food and Drug Administration (FDA) about the potential use of artificial intelligence to speed up the drug review process, Wired reports, citing its own sources.
According to the publication, the subject of the negotiations was the cderGPT project, an AI-based tool that is supposedly being developed for the Center for Drug Evaluation (CDE), a division of the FDA responsible for regulating both prescription and over-the-counter drugs in the United States.
It is also noted that representatives of DOGE, a structure associated with Elon Musk, joined the discussions.
Wired notes that the full development cycle for new drugs often takes more than a decade. OpenAI's technologies could help shorten at least part of this process — especially in the final stages.
AI has long been seen as a promising tool for optimizing certain stages of pharmaceutical research, but questions remain about the accuracy of such models and control for possible errors.